Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply
- PMID: 36427521
- DOI: 10.1016/S2213-8587(22)00310-2
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply
Conflict of interest statement
JC reports research grants and personal fees from Servier for the ADVANCE and PROGRESS trials, and grants from the National Health and Medical Research Council of Australia for these two trials. RRH reports research support from AstraZeneca, Bayer, and MSD; and personal fees from Anji Pharmaceuticals, Bayer, Novartis, and Novo Nordisk. KR reports personal fees from the BMJ Heart and PLOS Medicine, outside of the submitted work. MN and AIA declare no competing interests.
Comment on
-
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.Lancet Diabetes Endocrinol. 2022 Sep;10(9):645-654. doi: 10.1016/S2213-8587(22)00172-3. Epub 2022 Jul 22. Lancet Diabetes Endocrinol. 2022. PMID: 35878651 Free PMC article.
-
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes.Lancet Diabetes Endocrinol. 2022 Dec;10(12):840. doi: 10.1016/S2213-8587(22)00312-6. Lancet Diabetes Endocrinol. 2022. PMID: 36427519 No abstract available.
-
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes.Lancet Diabetes Endocrinol. 2022 Dec;10(12):840-841. doi: 10.1016/S2213-8587(22)00311-4. Lancet Diabetes Endocrinol. 2022. PMID: 36427520 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
